Diroximel fumarate

Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS).[1][3][4]

Diroximel fumarate
Clinical data
Trade namesVumerity
Other namesALKS-8700
AHFS/Drugs.comMonograph
MedlinePlusa620002
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC11H13NO6
Molar mass255.226 g·mol−1
3D model (JSmol)
  • COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O
  • InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+
  • Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N

Diroximel fumarate was approved for medical use in the United States in October 2019,[5] and in the European Union in November 2021.[2]

History

This drug was formulated by Alkermes in collaboration with Biogen.[6]

Society and culture

Diroximel fumarate was approved for medical use in the United States in October 2019.[5]

On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vumerity, intended for the treatment of adults with relapsing remitting multiple sclerosis.[7] The applicant for this medicinal product is Biogen Netherlands B.V.[7] It was approved for medical use in the European Union in November 2021.[2]

References
  1. "Vumerity- diroximel fumarate capsule". DailyMed. Retrieved 1 February 2021.
  2. "Vumerity EPAR". European Medicines Agency. 14 September 2021. Retrieved 24 November 2021.
  3. Wang Y, Bhargava P (July 2020). "Diroximel fumarate to treat multiple sclerosis". Drugs of Today. 56 (7): 431–437. doi:10.1358/dot.2020.56.7.3151521. PMID 32648853. S2CID 220471534.
  4. Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E (October 2020). "Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?". Pharmaceuticals (Basel, Switzerland). 13 (10): 306. doi:10.3390/ph13100306. PMC 7602023. PMID 33066228.
  5. "Drug Approval Package: Vumerity". U.S. Food and Drug Administration (FDA). 21 April 2020. Retrieved 1 February 2021.
  6. "Diroximel fumarate".
  7. "Vumerity: Pending EC decision". European Medicines Agency. 15 September 2021. Retrieved 17 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.